Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have received a consensus rating of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, thirteen have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $148.19.

Several research firms have issued reports on MIRM. Stifel Nicolaus boosted their price objective on shares of Mirum Pharmaceuticals from $136.00 to $156.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. Royal Bank Of Canada lifted their target price on Mirum Pharmaceuticals from $135.00 to $155.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. Weiss Ratings downgraded shares of Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday. Evercore reissued an “outperform” rating and set a $146.00 price target on shares of Mirum Pharmaceuticals in a research report on Tuesday, October 13th. Finally, Morgan Stanley raised their price target on shares of Mirum Pharmaceuticals from $137.00 to $152.00 and gave the company an “overweight” rating in a report on Monday, October 12th.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ:MIRM opened at $80.39 on Wednesday. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals has a 12 month low of $63.23 and a 12 month high of $130.00. The company has a market capitalization of $5.22 billion, a price-to-earnings ratio of -5.53 and a beta of 0.61. The firm’s 50-day moving average is $91.43 and its 200 day moving average is $100.32.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The firm had revenue of $176.24 million during the quarter, compared to the consensus estimate of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%. The firm’s revenue for the quarter was up 37.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.12) EPS. Research analysts predict that Mirum Pharmaceuticals will post -1.32 EPS for the current year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 6,001 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total value of $599,499.90. Following the transaction, the chief financial officer directly owned 36,355 shares of the company’s stock, valued at approximately $3,631,864.50. The trade was a 14.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total value of $2,960,400.00. Following the transaction, the chief executive officer directly owned 194,440 shares in the company, valued at approximately $19,187,339.20. The trade was a 13.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 98,499 shares of company stock worth $9,797,834 in the last 90 days. 8.32% of the stock is owned by corporate insiders.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC raised its stake in Mirum Pharmaceuticals by 14.5% in the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after buying an additional 880,505 shares during the last quarter. Jupiter Topco LLC purchased a new stake in shares of Mirum Pharmaceuticals during the second quarter worth about $691,672,000. BlackRock Inc. acquired a new position in shares of Mirum Pharmaceuticals during the second quarter valued at about $513,945,000. William Blair Investment Management LLC acquired a new position in shares of Mirum Pharmaceuticals during the second quarter valued at about $164,453,000. Finally, Rock Springs Capital Management LP increased its holdings in shares of Mirum Pharmaceuticals by 6.4% during the first quarter. Rock Springs Capital Management LP now owns 811,294 shares of the company’s stock valued at $74,947,000 after acquiring an additional 49,000 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company’s medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.